List view / Grid view
Drug Target Review's Ria Kakkad spoke with Victoria Goldenshtein at PEGs Europe, about her lab’s novel in vitro library display platform for directed protein evolution called GRIP display – gluing RNA to its proteins.
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
30 January 2023 | By Thermo Fisher Scientific
Watch this webinar to learn how an integrated structural biology workflow can be used to get crucial structural insights on key protein targets that are of therapeutic interest.
US researchers have found that G protein-coupled receptors function in a way not previously known, which suggests untapped potential.
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Jonathan Javitch, Professor at Columbia University’s Vagelos College of Physicians and Surgeons, about the cutting-edge imaging method single-molecule fluorescence resonance energy transfer (smFRET), used to investigate G protein-coupled receptors (GPCRs).
Dr Erik Vernet, Director of Antibody Technology at Novo Nordisk, discusses antibody discovery and development workflows, including the role of informatics processes, in this Q&A.
The new high-throughput screening method identified nine lead molecules for rhodopsin dimerisation that may lead to next-generation medicines.
A new computer-aided tool maps allosteric sites in G protein-coupled receptors to search for allosteric drugs to treat a range of diseases.
Learn how you can partner for success with Eurofins Beacon Discovery’s industry leading GPCR experts to support your program from concept to clinic.
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
Hannah Balfour explores how genetic variation in G-protein-coupled receptors (GPCRs) and the proteins that regulate the duration of G protein signalling could be contributing to disease and people’s divergent responses to the same therapeutics.
4 June 2020 | By Biosensing Instrument
In this webinar, we will provide an overview of the technology with some application examples and also see a case study how AstraZeneca is exploring SPRM for studies on G-protein-coupled receptors (GPCR) in close collaboration with Biosensing Instrument.
A team used both structural and spectroscopic techniques to study the dynamics of cell surface G-protein coupled receptors (GPCRs).
Therapeutic monoclonal antibodies are proven and effective treatment options but many of the ‘low-hanging fruit’ therapeutics have already been identified.
